Dermalyser Receives CE Mark In Europe, Paving Way to Market for World’s Best Melanoma Diagnostic Decision Support Tool - Business News Week

Dermalyser Secures CE Mark in Europe for AI-Powered Melanoma Detection Tool

AI Medical Technology launches Dermalyser, an AI tool for melanoma diagnosis, enhancing detection accuracy and skin cancer care in Europe.

Of the 332,000 cases of skin melanoma worldwide in 2022, 83% are attributed to UV rays.

While skin melanoma was "rare in the past", increased exposure to UV in recent decades (tanning, travel, etc.) has led to a sharp increase in cases, particularly among populations with low levels of UV radiation.

Dermalyser Receives CE Mark In Europe, Paving Way to Market for World’s Best Melanoma Diagnostic Decision Support Tool - Business News Week

Stockholm, Sweden. May 27, 2025 – AI Medical Technology has received European CE mark approval for Dermalyser, its smartphone-based diagnosis decision support tool designed for melanoma detection. The efficacy of Dermalyser, which is classified as a stand-alone Medical Device Software (MDSW), has been confirmed in clinical studies, however for the CE mark process, data from […] The post Dermalyser Receives CE Mark In Europe, Paving Way to Market…